Protuoso Biosciences develops multifunctional MUXBODIES™, fully recombinant fusion proteins designed to integrate antibodies, cytokines, peptides and other signaling modules into single therapeutics that can exert multi-modal functions. Its platform combines computational protein design, massively parallel synthetic biology, and AI-enabled modular protein engineering to optimize multi-domain fusion proteins. The company is building a hub-and-spoke operating model: a central engineering hub that generates diverse assets and spokes that advance programs in parallel and enable early business development. Protuoso has active programs in cardiometabolic diseases, solid tumors (including armored immune cell engagers) and is expanding into autoimmune indications. The company is headquartered in San Carlos, Calif., and positions its model to drive capital efficiency and create multiple value inflection points across the pipeline.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

May 2026